IP Library Patent Application 15181726
Patent Application
App. No. 15/181,726

ADMINISTRATION OF SYNERGISTIC AMOUNTS OF MODIFIED CITRUS PECTIN AND HONOKIOL TO TREAT INFLAMMATION AND ANTI-OXIDANT NEEDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/181,726
Abstract

A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents.

Claims (9)

1 . A method of inhibiting or reducing inflammation in a mammal in need of same, comprising:

a) Selecting a mammal in need of inhibition of inflammation or reduction of inflammation;

b) Administering to said mammal selected a combination of honokiol and modified citrus pectin (MCP) in amounts which exhibit synergy in the reduction or inhibition of inflammation for a period of time sufficient to achieve the needed inhibition or reduction of inflammation in said mammal.

2 . The method of claim 1 , wherein said honokiol and said MCP are administered, independently, to said mammal orally, intravenously, parenterally, rectally, vaginally or intramuscularly.

3 . The method of claim 2 , wherein said honokiol is administered in an amount (as oral equivalents) of 5-500 mg/kg of body weight/day and said MCP is administered) in oral equivalents) of 10-700 mg/kg/day

4 . The method of claim 1 , wherein said need for reduction or inhibition of inflammation is due to the potential for acute inflammation.

5 . The method of claim 1 , wherein said need for reduction or inhibition of inflammation is due to chronic inflammation

6 . The method of claim 1 , wherein said need for reduction or inhibition of inflammation is due to inflammation of at least one of the heart, liver, lungs, kidneys, brain, circulatory system and digestive system.

7 . The method of claim 1 , wherein said need for reduction or inhibition of inflammation is caused by the presence, in the mammal selected, of cancer, autoimmune disease, arthritis, neurological disorder, hormonal imbalance, cardiovascular disease, kidney disease, liver disease, lung disease, and an immune disorder.

Assignments (2)
SECURITY INTEREST Recorded Dec 20, 2024
From: ECONUGENICS, LLC
To: ANTARES CAPITAL LP, AS COLLATERAL AGENT
Reel/Frame 069649/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2016
From: ELIAZ, ISAAC
To: ECONUGENICS, INC.
Reel/Frame 039081/0807 →